Clinical research on the efficacy of pilocarpine hydrochloride administration from the early stage of treatment for the reduction of oral mucositis in oral cancer radiation therapy.

Clinical research on the efficacy of pilocarpine hydrochloride administration from the early stage of treatment for the reduction of oral mucositis in oral cancer radiation therapy. - Clinical research on the efficacy of pilocarpine hydrochloride administration.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036529

Enrollment

Registered

2019-05-31

Start date

2019-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral mucositis in oral cancer radiation therapy

Interventions

Oral administration of pilocarpine hydrochloride. A dose of 5mg will be taken orally after meals three times a day, and the administration period will be 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who undergo SSIACRT for oral cancer. 2)Patients with no history of radiation exposure to the head and neck. 3)Patients who have not had surgery for salivary gland disease in the past. 4)Patients who do not notice symptoms of xerostomia prior to SSIACRT.

Exclusion criteria

Exclusion criteria: 1)Patients who fall under contraindications in the package insert. 2)Patients taking medications with interaction. 3)Patients judged to be inappropriate by their doctor.

Design outcomes

Primary

Measure	Time frame
Period of oral intake	—

Secondary

Measure	Time frame
Severity of oral mucositis, and amount of saliva secretion at rest	—

Countries

Japan

Contacts

Public ContactYusuke Tanaka

Hirosaki University Hospital Department of Oral and Maxillofacial Surgery

tanayuu820@hirosaki-u.ac.jp0172-39-5127

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026